Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Authors Abouelfadel Z, Crawford ED

Published 11 April 2008 Volume 2008:4(2) Pages 513—526


Zinelabidine Abouelfadel1,2, E David Crawford1

1Urologic Oncology, University of Colorado Cancer Center, Aurora, CO, USA; 2Currently, Amiri Hospital Kuwait University, Urology Section, Kuwait City

Abstract: Hormone therapy is well established for treating patients with prostate cancer and remains the mainstay of the treatment of metastatic and locally advanced disease, this article reviews the rationale for its use, its different forms, and complications and controversies still surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormone-releasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, and helped to avoid the emotional and psychological effects related to surgical castration. The depot formula has gained wide acceptance from both patients and physicians. This review emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 6-month formula, its advantage over over shorter-acting depot products, and its potential to become a standard of care for patients eligible for androgen deprivation therapy.

Keywords: prostate cancer, androgen deprivation therapy (adt), leuprorelin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema

Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW

Clinical Ophthalmology 2014, 8:1611-1621

Published Date: 26 August 2014

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP

Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P

OncoTargets and Therapy 2014, 7:587-597

Published Date: 23 April 2014

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells

Shi S, Jia J, Guo X, Zhao Y, Chen D, Guo Y, Cheng T, Zhang X

International Journal of Nanomedicine 2012, 7:5593-5602

Published Date: 25 October 2012

Valproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome

Thorsten Gerstner, Nellie Bell, Stephan A Koenig

Therapeutics and Clinical Risk Management 2008, 4:645-647

Published Date: 6 June 2008

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists

Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, Jeffrey M Jacobson

Therapeutics and Clinical Risk Management 2008, 4:473-485

Published Date: 11 April 2008

Adalimumab in the treatment of arthritis

Philip J Mease

Therapeutics and Clinical Risk Management 2007, 3:133-148

Published Date: 15 March 2007